The Scientist

» drug development and immunology

Most Recent

image: Targeting Protein Domains with CRISPR

Targeting Protein Domains with CRISPR

By | May 13, 2015

Researchers use the genome-editing tool to mutate binding pockets and identify potential anti-cancer drug targets.

0 Comments

image: Measles Vax’s Off-Target Effects

Measles Vax’s Off-Target Effects

By | May 11, 2015

Researchers find evidence that measles vaccines reduced deaths from other infectious diseases due to “immune amnesia.”

2 Comments

image: Outsmarting HIV

Outsmarting HIV

By | May 4, 2015

Small molecules that mimic the T-cell surface receptor CD4 could expose the virus to antibody-based immune responses.

0 Comments

image: Filippos Porichis: Immunoregulator

Filippos Porichis: Immunoregulator

By | May 1, 2015

Principal Investigator, Ragon Institute of MGH, MIT, and Harvard. Age: 33

0 Comments

image: Llamas as Lab Rats

Llamas as Lab Rats

By | May 1, 2015

From diagnostics to vaccines, llama antibodies point to new directions in HIV research.

0 Comments

image: Looking for Latent HIV

Looking for Latent HIV

By | May 1, 2015

Sequencing HIV integration sites suggests that clonally expanded T-cell populations may not be the main source of latent virus.

0 Comments

image: Soluble Signal

Soluble Signal

By | May 1, 2015

An immune protein previously thought to mark inactive T cells has a free-floating form that correlates with HIV disease progression.

0 Comments

image: Defeating the Virus

Defeating the Virus

By | May 1, 2015

Recent discoveries are spurring a renaissance in HIV vaccine research and development.

0 Comments

image: RNA Ebola Drug Clears Animal Study

RNA Ebola Drug Clears Animal Study

By | April 24, 2015

The short interfering RNA-based therapy TKM-Ebola protects monkeys from the viral strain still circulating in West Africa.

0 Comments

image: FDA Calls for Data on ALS Drug

FDA Calls for Data on ALS Drug

By | April 21, 2015

In the midst of a debate about an experimental drug’s early approval, the US Food and Drug Administration requests that full trial results be released.

1 Comment

Popular Now

  1. Opinion: Why I Published in a Predatory Journal
    News & Opinion Opinion: Why I Published in a Predatory Journal

    My “colleagues” and I at the fictitious Arthur Vandelay Urological Research Institute were surprised to find our bogus “uromycitisis” case report swiftly accepted, with only minor revisions requested.

  2. Consilience, Episode 3: Cancer, Obscured
  3. March for Science: Dispatches from Washington, DC
  4. Record-Setting Corn Grows 45 Feet Tall
AAAS